диссертации / 129

131

17)Лупинская, З.А. Эндотелий: функция и дисфункция /

З.А.Лупинская, А.Г.Зарифьян, Т.Ц.Гурович, С.Г.Шлейфер. – Бишкек:

КРСУ, 2008. – 373 с.

18)Малая, Л.Т. Эндотелиальная дисфункция при патологии сердечно-

сосудистой системы / Л.Т.Малая, А.Н.Корж, Л.Б.Балковая. – Харьков:

Форсинг, 2000. – 432 с.

19)Марков, Х.М. Молекулярные механизмы дисфункции сосудистого эндотелия / Х.М.Марков // Кардиология. – 2005. - №12. – С. 62 – 72.

20)Новикова, Н.В. Патофизиологические механизмы воздействия табакокурения на сердечно-сосудистую систему (обзор литературы) /

Н.В.Новикова, А.И.Кодочигова, В.Ф.Киричук, Д.С.Новиков, В.Г.Халтурина // Саратовский научно-медицинский журнал. – 2007. – №3

(17). – С. 49-52.

21) Павлов, А.Ю. Изменения внутримозговых сосудов и регионального мозгового кровотока при рассеянном склерозе / А.Ю.Павлов, Г.Н.Бисага, В.С.Декан, С.Д.Рудь, О.Н.Гайкова, Л.С.Онищенко // Вест. Росс. Воен.-

мед. акад. – 2008. – № 4. – С. 66-72.

22)Рассеянный склероз / Под ред. Е.И.Гусева, И.А.Завалишина, А.Н.Бойко – М.: Реал Тайм, 2011. – 528 с.: ил.

23)Спирина, Н.Н. Фактор фон Виллебранда и молекулы адгезии у

пациентов с рассеянным склерозом / Н.Н.Спирин, Н.Н.Спирина, А.Н.Бойко // Журнал неврологии и психиатрии им. С.С. Корсакова. –

2014. – № 2. – С. 35-39.

24) Петрищев, Н.Н. Физиология и патофизиология эндотелия. Дисфункция эндотелия. Причины, механизмы. Фармакологическая коррекция / Н.Н.Петрищев, Т.Д.Власов Под ред. Н.Н. Петрищева. – СПб.: СПб ГМУ, 2003. – 97 c.

132

25) Чернявская, Т.К. Современные подходы к диагностике и коррекции эндотелиальной дисфункции у пациентов с артериальной гипертонией /

Т.К.Чернявская // Лечебное дело. – 2013. – №2. – С. 118-130.

26) Шарафутдинова, Л. Р. Курение как фактор риска развития и прогрессирования рассеянного склероза (обзор и собственные данные) /

Л.Р.Шарафутдинова, Р.В.Магжанов, А.Р.Рахматуллин, К.З.Бахтиярова // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2013. – №10. – С. 18-22.

27)Шляхто, Е.В. Современные представления о дисфункции эндотелия и методах ее коррекции при атеросклерозе / Е.В.Шляхто, О.А.Беркович, Л.Б.Беляева и др. // Международ. Невролог. журнал. – 2002. – №3. – С. 9- 13.

28)Abbott, N.J. Astrocyte-endothelial interactions at the blood-brain barrier / N.J.Abbott, L.Ronnback, E.Hansson // Nat. Rev. Neurosci. – 2006. – V. 7. –

P.41–53.

29)Adams, C.W.M. Inflarnmatory vasculitis in multiple sclerosis / C.W.M.Adams, R.N.Poston, S.J.Buk et al. // J. Neurol. Sci. – 1985. – V. 69. –

P.269—283.

30)Adams, C.W. Perivascular iron deposition and other vascular damage in multiple sclerosis / C.W.Adams // J. Neurol. Neurosurg. Psychiatry. – 1988. –

V.51 (2). – P. 260–265.

31)Adamson, P. Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling / P.Adamson,

B.Wilbourn, S.Etienne-Manneville, V.Calder, E.Beraud et al. // FASEB J. –

2002. – V. 16. – P. 1185-1194.

133

32)Albelda, S. EndoCAM: a novel endothelial cell-cell adhesion molecule / S.Albelda, P.Oliver, L.Romer, C.Buck // J. Cell. Biol. – 1990. – V. 110. – P. 1227–1237.

33)Allt, G. Is the pial microvessel a good model for blood-brain barrier studies? / G.Allt, J.G.Lawrenson // Brain. Res. Brain. Res. Rev. – 1997. – V. 24(1). – P. 67–76.

34)Baracchini, C. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset / C.Baracchini, P.Perini, M.Calabrese, F.Causin, F.Rinaldi et al. // Ann. Neurol. – 2011. – V. 69(1). – P. 90–99.

35)Barilaro, A. Kinetic of brain MRI gadolinium enhancing lesions in multiple sclerosis / A.Barilaro, F.Zellini, F.Caleri et al. // European Journal of Neurology. – 2004. – V.11. – P. 20.

36)Bataille R. C–reactive protein levels as a direct indicator of interleukin–6 levels in humans in vivo / R.Bataille, B.Klein // Arthritis Rheum. – 1992. – V. 35(8). – P. 982–984.

37)Bernal, F. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in MS patients / F.Bernal, B.Elias, H.P.Hartung, B.C.Kieseir // Mult. Scler. – 2009. – V. 15(6). – P. 721–727.

38)Blann, A.D. Von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease / A.D.Blann // J. Reumatol. –

1993. – V. 20(9). – P. 1469-1471.

39)Bogen S. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo / S.Bogen, J.Pak, M.Garifallou, X.Deng, W.Muller // J. Exp. Med. – 1994. – V. 179(3). – P. 1059-1064.

40)Brooks, T.A. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations / T.A.Brooks,

134

B.T.Hawkins, J.D.Huber, R.D.Egleton, T.P.Davis // Am. J. Physiol. Heart.

Circ. Physiol. – 2005. – V. 289(2). – P. H738-743.

41)Butt, A.M. Effect of histamine and antagonists on electrical resistance across the blood-brain barrier in rat brain-surface microvessels / A.M.Butt, H.C.Jones // Brain. Res. – 1992. – V. 569(1). – P. 100–105.

42)Butt, A.M. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study / A.M.Butt, H.C.Jones, N.J.Abbott // J. Physiol. – 1990. – V. 429. – P. 47–62.

43)Canella, B. The adhesion molecule and cytokine profile of multiple sclerosis lesions / B.Canella, C.S.Raine // Ann. Neurol. – 1995. – V. 37(4). – P. 424 – 435.

44)Celermajer, D.S. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis / D.S.Celermajer, K.Sorensen, V.Gooch, D.J.Spiegelhalter, O.I.Miller et al. // Lancet. – 1992. – V. 340. – P. 1111-1115.

45)Centonze D. Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity / D.Centonze, R.Floris, M.Stefanini, S.Rossi, S.Fabiano et al. // Ann. Neurol. – 2011. – V. 70(1). – P. 51–58.

46)Chi, J.T. Endothelial cell diversity revealed by global expression profiling / J.T.Chi, H.Y.Chang, G.Haraldsen, F.L.Jahnsen, O.G.Troyanskaya, et al. // Proc. Natl. Acad. Sci. USA. – 2003. – V. 100(19). – P. 10623– 10628.

47)Cines, D.B. Endothelial Cells in Physiology and in the Pathophysiology of Vascular Disorders / D.B.Cines, E.S.Pollak, A.C.Buck, J.Loscalzo, G.A.Zimmerman et al. // Blood – 1998. – V. 91(10). – P.3527-3561.

135

48)Cox, M.B. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation / M.B.Cox, N.A.Bowden, R.J.Scott, J.Lechner-Scott // Mult. Scler. – 2013. – V. 19(10). – P. 1268-1274.

49)D’haeseleer, M. Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1 / M.D’haeseleer, R.Beelen, Y.Fierens,

M.Cambron, A.M.Vanbinst et al. // J. Proc. Natl. Acad. Sci. USA. – 2013. – V.

110(14). – P. 5654–5658.

50)D’haeseleer, M. Vascular aspects of multiple sclerosis / M.D’haeseleer,

M.Cambron, L.Vanopdenbosch, J.D.Keyser // The Lancet Neurology. – 2011.

– V. 10(7). – P. 657-666.

51)De Vries, H.E. The blood-brain barrier in neuroinflammatory diseases / H.E.De Vries, J.Kuiper, A.G.de Boer, T.J.C.van Berkel, D.D.Brimer // Pharmacol. Rev. – 1997. – V. 49. – P. 143-155.

52)Debernard, L. Reduced grey matter perfusion without volume loss in early relapsing-remittingmultiple sclerosis / L.Debernard, T.R.Melzer, S.Van Stockum, C.Graham, C.A.Wheeler-Kingshott et al. // J. Neurol. Neurosurg. Psychiatry. – 2014. – V. 85(5). – P. 154–160.

53)Dinca L.P. Serum endothelial adhesion molecules levels correlate with lesion burden in multiple sclerosis patients treated with interferon beta-1b /

L.P.Dinca, M.Lucas, M.D.Zayas, M.A.Muñoz, J.M.Garcia Moreno et al. // Neurochem. Int. – 2000. – V. 36(6). – P. 549-553.

54) Doepp, F. No cerebrocervical venous congestion in patients with multiple sclerosis / F.Doepp, F.Paul, J.M.Valdueza, K.Schmierer, S.J.Schreiber // Ann. Neurol. – 2010. – V. 68(2). – P. 173–183.

136

55)Doerck, S. Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis / S.Doerck, K.Göbel, G.Weise, T.Schneider-Hohendorf, M.Reinhardt et al. // PLoS One. – 2010. – V. 5(11). – P. e15478.

56)Dore-Duffy, P. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity / P.Dore-Duffy, W.Newman, R.Balabanov, R.P.Lisak, E.Mainolfi et al. // Ann. Neurol. – 1995. – V. 37(1). – P. 55-62.

57)Droogan, A.G. Effects of intravenous methylprednisolone therapy on leukocyte and soluble adhesion molecule expression in MS / A.G.Droogan, A.D.Crockard, S.A.McMillan, S.A.Hawkins // Neurology. – 1998. – V. 50(1).

– P. 224-229.

58)Droogan, A.G. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1 / A.G.Droogan, S.A.McMillan, J.P.Douglas, S.A.Hawkins // J. Neuroimmunol. – 1996. – V. 64(2). – P. 185-191.

59)Dyment, D.A. Multiple sclerosis in stepsiblings: recurrence risk and ascertainment / D.A.Dyment, I.M.Yee, G.C.Ebers, A.D.Sadovnick, Canadian Collaborative Study Group // J. Neurol. Neurosurg. Psychiat. – 2006. – V. 77

(2). – P. 258—259.

60)El-Gabalawy, H. Epidemiology of immunemediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities / H.ElGabalawy, L.C.Guenther, C.N.Bernstein // J. Rheumatol. Suppl. – 2010. – V. 85. – P. 2–10.

61)Elovaara, I. Adhesion molecules in multiple sclerosis: Relation to subtypes of disease and methylprednisolone therapy / I.Elovaara, M.Ukkonen,

137

M.Leppäkynnäs, T.Lehtimäki, M.Luomala et al. // Arch. Neurol. – 2000. – V.

57(4). – P. 546-551.

62)Endemann, D.H. Endothelial Dysfunction / D.H.Endemann, E.L.Schiffrin // J. Am. Soc. Nephrol. – 2004. – V.15. – P.1983-1992.

63)Engelhardt, B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines / B.Engelhardt // J. Neurol. Sci. – 2008. – V. 15; 274(1-2). – P. 23-26.

64)Etienne, S. ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells / S.Etienne, P.Adamson, J.Greenwood, A.D.Strosberg, S.Cazaubon et al. // J. Immunol. – 1998. – V. 161(10). – P. 5755-5761.

65)Fernandes, K.S. Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients / K.S.Fernandes, D.G.Brum, A.C.Palei, V.C.Sandrim, C.T.Guerreiro et al. // J. Neuroimmunol. – 2012. – V. 249(1-2). – P. 56-59.

66)Fjeldstad, A.S. Vascular function and multiple sclerosis / A.S.Fjeldstad, J.McDaniel, M.A.Witman, S.J.Ives, J.Zhao et al. // J. Neurol. – 2011. – V. 258(11). – P. 2036-2042.

67)Gabay, C. Acute–phase proteins and other systemic responses to inflammation / C.Gabay, I.Kushnewr // N. EngI. J. Med. – 1999. – V. 340(6). – P. 448–454.

68)Gaitán, M.I. Initial investigation of the blood-brain barrier in MS lesions at 7 tesla / M.I.Gaitán, P.Sati, S.J.Inati, D.S.Reich // Mult. Scler. – 2013. – V. 19(8). – P. 1068-1073.

138

69)Gaitán, M.I. Evolution of the Blood-Brain Barrier in Newly Forming Multiple Sclerosis Lesions / M.I.Gaitán, C.D.Shea, I.E.Evangelou, R.D.Stone, K.M.Fenton et al. // Ann. Neurol. – 2011. – V. 70(1). – P. 22–29.

70)Gamboa, A. Role of Adenosine and Nitric Oxide on the Mechanisms of Action of Dipiridamole / A.Gamboa, R.Abraham, A.Diedrich, C.Shibao, S.Y.Paranjape et al. // Stroke. – 2005. – V. 36(10). – P. 2170-2175.

71)Ge, S. Where is the blood-brain barrier... really? / S.Ge, L.Song, J.S.Pachter // J. Neurosci. Res. – 2005. – V. 79(4). – P. 421–427.

72)Ge, Y. Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity / Y.Ge, M.Law, G.Johnson, J.Herbert, J.S.Babb et al. // AJNR Am. J. Neuroradiol. – 2005. – V. 26(6). – P. 1539–1547.

73)Giovannoni, G. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging / G.Giovannoni, M.Lai, J.Thorpe, D.Kidd, V.Chamoun et al. // Neurology. – 1997. – V. 48(6). – P. 1557-1565.

74)Giovannoni, G. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease / G.Giovannoni, J.W.Thorpe, D.Kidd, B.E.Kendall, I.F.Moseley et al. // J. Neurol. Neurosurg. Psychiatry. – 1996. – V. 60(1). – P. 20-26.

75)Graesser, D. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1–deficient mice / D.Graesser, A.Solowiej, M.Bruckner, E.Osterweil, A.Juedes et al. // J. Clin. Invest. – 2002. – V. 109(3). – P. 383–392.

76)Griendling, K.K. NADH/NADPH oxidase and vascular function / K.K.Griendling, M.Ushio-Fukai // Trends cardiovasc. Med. – 1997. – V. 7. – P. 301-307.

139

77)Hansson, G.K. The immune system in atherosclerosis / G.K.Hansson, A.Hermansson // Nat. Immunol. – 2011. – V. 12(3). – P. 204–212.

78)Harrison, D.G. Cellular and molecular mechanism of endothelial cell dysfunction / D.G. Harrison // J. Clin. Investig. – 1997. – № 100. – P. 21532157.

79)Haselhorst, R. Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction / R.Haselhorst, L.Kappos, D.Bilecen, K.Scheffler,

D.Möri et al. // J. Magn. Reson. Imaging. – 2000. – V. 11(5). – P. 495–505.

80)Hladovec, J. Circulating endothelial cells in acute myocardial infarction and angina pectoris / J.Hladovec, I.Prerovsky, V.Stanek, J.Fabian // Klin. Wochenschr. –1978. – V. 56(20). – P.1033-1036.

81)Horstman, L.L. Endothelial microparticles as markers of endothelial dysfunction/ L.L.Horstman, W.Jy, J.J.Jimenez, Y.S.Ahn // Front. Biosci. –

2004. – V. 1(9). – P. 1118-1135.

82)Huber, J.D. Alterations in blood-brain barrier ICAM-1 expression and

brain microglial activation after λ-carrageenan-induced inflammatory pain / J.D.Huber, C.R.Campos, K.S.Mark, T.P.Davis // Am. J. Physiol. Heart. Circ. Physiol. – 2006. – V. 290(2). – P. H732-740.

83)Inagami, T. Endothelium as an endocrine organ / T.Inagami, M.Naruse, R.Hoover // Annu. Rev. Physiol. – 1995. – V. 57. – P. 171-189.

84)Inglese, M. Deep Gray Matter Perfusion in Multiple Sclerosis: Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging at 3 T / M.Inglese, S.Park, G.Johnson, J.S.Babb, L.Miles et al. // Arch. Neurol. – 2007.

– V. 64(2). – P. 196-202.